Anika Therapeutics Inc
ANIK
NASDAQ
Biotechnology
$21.50
USD
+0.33 (+1.56%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $286.13M
Volume 124.9K
Revenue
$120.65M
TTM
+5.3%
YoY
Gross Margin
62%
TTM
+8.6%
YoY
Net Income
$-3.78M
TTM
+93.8%
YoY
Operating Cash Flow
$5.98M
TTM
-4.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 28.2 | 27.8 | 30.6 | 29.6 | 32.6 |
YoY Growth | -8.2% | -5.9% | +0.0% | +13.2% | +15.6% |
Cost of Revenue | 13.9 | 12.2 | 11.4 | 10.6 | 11.4 |
Gross Profit | 14.4 | 15.6 | 19.2 | 19.0 | 21.2 |
Selling, General & Administrative | 12.2 | 11.9 | 12.1 | 17.8 | 10.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 18.5 | 18.8 | 18.5 | 24.5 | 18.3 |
Operating Income | -4.2 | -3.2 | 0.6 | -5.5 | 3.0 |
EBITDA | -2.8 | -1.8 | 2.0 | -4.1 | 4.5 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 0.2 | 1.0 | 0.1 | 0.7 | 0.4 |
Income Before Income Taxes | -4.0 | -2.2 | 0.8 | -4.8 | 3.4 |
Income Taxes | 0.7 | 0.9 | -1.0 | 0.2 | 0.1 |
Net Income | -4.0 | -2.3 | 0.3 | -5.1 | 3.3 |
Consolidated Net Income / Loss | -4.0 | -2.3 | 0.3 | -5.1 | 3.3 |
Net Income Attributable to Common Shareholders | -4.0 | -2.3 | 0.3 | -5.1 | 3.3 |
Basic EPS | -$0.28 | -$0.16 | $0.02 | -$0.37 | $0.25 |
Diluted EPS | -$0.28 | -$0.16 | $0.02 | -$0.37 | $0.24 |
Basic Shares Outstanding | 14.4M | 14.4M | 14.3M | 13.5M | 13.3M |
Diluted Shares Outstanding | 14.5M | 14.4M | 14.1M | 13.5M | 13.7M |